Session » Infection Related Rheumatic Diseases

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1137

Evaluating Indeterminate Quantiferon-TB Gold In-Tube Results in Patients With Chronic Inflammatory Diseases On Immunosuppressive Therapy

Abstract Number: 1138

Tuberculin Skin Test and Booster Phenomenon In a Rheumatoid Arthritis Population. Differences Between Early and Established Disease

Abstract Number: 1139

Pyogenic Arthritis: Clinical and Epidemiological Features Of 101 Cases At a University Hospital

Abstract Number: 1140

Study Of The Antibody Titer By Influenza Vaccination In Rheumatoid Arthritis Patients Treated With Biologics In JAPAN

Abstract Number: 1141

Response To H. Pylori Treatment and Autoantibody In Chronic Thrombocytopenia

Abstract Number: 2806

Low Risk Of Hepatitis B Virus Surface Antigen Seroreversion In HBsAg Negative/Anti-Hbc Positive Carriers Undergoing Rituximab For Rheumatoid Arthritis

Abstract Number: 2807

Management Of Vertebral Osteomyelitis: A Randomized Clinical Trial Comparing 6 Versus 12 Weeks Of Antibiotic Treatment

Abstract Number: 2808

Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants

Abstract Number: 2809

Prevalence and Clinical Presentation Of Lyme Arthritis In a Large Cohort Of Patients With Recent-Onset Arthritis

Abstract Number: 2810

Follow-Up Testing Of Interferon-Gamma Release Assays For The Diagnosis Of Hidden Tuberculosis Infection In Patients Receiving Tumor Necrosis Factor Alpha Antagonists

Abstract Number: 2811

Disease Characteristics and Treatment Patterns In US Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.